pharmaphorum November 22, 2022
Musk’s arrival at the social platform has raised questions for users, which includes pharma companies who use Twitter for marketing and patients who utilise it to engage with their medical communities. Ben Hargreaves explores how the current uncertainty surrounding Twitter could dissuade both from using the platform.
Elon Musk’s protracted takeover of Twitter has drawn attention ever since it was revealed that he had begun investing in the social media company at the beginning of the year. Eventually, Musk reached a deal to acquire the company in April, only to then attempt to cancel the agreement, as he raised questions over the level of spam accounts on the network. At the end of October, the deal finally went ahead at...
Today's Sponsors
Today's Sponsor